Log in

NASDAQ:NVCRNovocure Stock Price, Forecast & News

$63.34
-2.94 (-4.44 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$62.80
Now: $63.34
$65.76
50-Day Range
$57.05
MA: $73.97
$95.75
52-Week Range
$41.51
Now: $63.34
$98.84
Volume1.05 million shs
Average Volume1.25 million shs
Market Capitalization$6.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.31 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock been impacted by COVID-19 (Coronavirus)?

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has decreased by 6.0% and is now trading at $63.34. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novocure.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, February, 27th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. The medical equipment provider earned $99.23 million during the quarter, compared to analyst estimates of $99.10 million. Novocure had a negative return on equity of 4.17% and a negative net margin of 2.06%. The business's revenue was up 42.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) EPS. View Novocure's earnings history.

What guidance has Novocure issued on next quarter's earnings?

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 equities research analysts have issued 1-year price targets for Novocure's stock. Their forecasts range from $79.00 to $97.00. On average, they anticipate Novocure's share price to reach $87.40 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View analysts' price targets for Novocure.

Has Novocure been receiving favorable news coverage?

News headlines about NVCR stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNovocure.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $63.34.

How big of a company is Novocure?

Novocure has a market capitalization of $6.31 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.  View additional information about Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel